Allakos FY2024 EPS Forecast Decreased by Leerink Partnrs

Allakos Inc. (NASDAQ:ALLK) – Leerink Partnrs decreased their FY2024 earnings per share estimates for Allakos in a report released on Wednesday, February 5th. Leerink Partnrs analyst T. Smith now forecasts that the company will post earnings per share of ($1.20) for the year, down from their previous estimate of ($1.19). The consensus estimate for Allakos’ current full-year earnings is ($1.16) per share. Leerink Partnrs also issued estimates for Allakos’ Q4 2024 earnings at ($0.20) EPS, FY2025 earnings at ($0.52) EPS, FY2026 earnings at ($0.33) EPS, FY2027 earnings at ($0.25) EPS and FY2028 earnings at ($0.17) EPS.

A number of other equities analysts have also commented on ALLK. Citizens Jmp lowered shares of Allakos from a “strong-buy” rating to a “hold” rating in a report on Monday, January 27th. Piper Sandler lowered Allakos from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 27th. Four equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. According to MarketBeat, Allakos has an average rating of “Hold” and a consensus target price of $2.00.

Allakos Price Performance

ALLK opened at $0.28 on Friday. Allakos has a fifty-two week low of $0.23 and a fifty-two week high of $1.69. The company’s 50 day moving average price is $0.94 and its two-hundred day moving average price is $0.87. The firm has a market capitalization of $24.92 million, a price-to-earnings ratio of -0.14 and a beta of 0.78.

Allakos (NASDAQ:ALLK) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.01.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Alta Partners Management Company L.P. bought a new position in Allakos during the fourth quarter worth $3,081,000. Point72 Asset Management L.P. acquired a new stake in Allakos during the 3rd quarter worth about $1,143,000. FMR LLC raised its position in shares of Allakos by 14.6% in the 3rd quarter. FMR LLC now owns 5,370,247 shares of the company’s stock worth $3,508,000 after acquiring an additional 685,623 shares in the last quarter. RBF Capital LLC lifted its stake in shares of Allakos by 45.9% in the 3rd quarter. RBF Capital LLC now owns 510,529 shares of the company’s stock valued at $333,000 after purchasing an additional 160,529 shares during the period. Finally, GSA Capital Partners LLP boosted its position in shares of Allakos by 11.9% during the 3rd quarter. GSA Capital Partners LLP now owns 794,896 shares of the company’s stock valued at $519,000 after purchasing an additional 84,750 shares in the last quarter. Institutional investors and hedge funds own 84.64% of the company’s stock.

Allakos Company Profile

Allakos Inc, a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company’s lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications.